Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females aged above 40 with a clinical diagnosis of COPD and current COPD symptoms~* Current or previous smoker with a smoking history of 10 or more pack years~* Lung function parameters: FEV1/FVC \< 70%, post-bronchodilator and post-bronchodilator FEV1 \< 80% of predicted normal value~Exclusion Criteria:~* History and/or current clinical diagnosis of asthma or atopic diseases such as allergic rhinitis~* Use of inhaled glucocorticosteroids within 4 weeks prior to Visit 2~* Any relevant cardiovascular disorder as judged by the investigator or any current respiratory tract disorder other than COPD.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- F 4.5 bid (Type: EXPERIMENTAL): Formoterol 4.5 ug twice daily (bid)
- F 9.0 bid (Type: EXPERIMENTAL): Formoterol 9.0 ug bid
- PBO (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).